Rather than a directory of researchers, MR Longevity is organised around major scientific challenges where collaboration can meaningfully advance healthy longevity.
Senescent cells and their effects on ageing.
Measuring ageing and intervention response.
Maintaining and restoring function.
Metabolism and mitochondrial health.
Reproductive ageing and menopause.
Cognitive resilience and neurodegeneration.
Immune-system change across the lifespan.
Muscle, bone, mobility, independence.
Validating interventions on ageing mechanisms.
Computation for complex health trajectories.
Turning prevention science into measurable population healthspan.
Who takes part
What it produces
Scientific missions guide project creation and MR Match connections across the mission.
Signals from current research shaping how these missions are prioritised, with the practical implication for collaboration and a link to the source.
Senescent cells accumulate with age and drive chronic inflammation and tissue dysfunction. Selective clearance and modulation strategies remain among the most actively studied interventions in ageing biology.
Needs validated biomarkers of senescent burden before clinical claims can be made responsibly.
Source: Cell, 2023López-Otín et al., Hallmarks of aging: an expanding universeEpigenetic, proteomic and functional measures increasingly agree on direction, but not magnitude. Consortium work is standardising how clocks are reported and validated.
Comparable endpoints make it possible to judge whether an intervention actually changes ageing trajectory.
Source: Cell, 2023Biomarkers of Aging Consortium, Biomarkers of aging for the identification and evaluation of longevity interventionsThymic involution, clonal expansion and inflammageing alter response to infection, cancer and vaccination, connecting ageing biology directly to mainstream clinical medicine.
A strong entry point for clinical validation partnerships within existing care pathways.
Source: Nature Immunology, 2021Mittelbrunn & Kroemer, Hallmarks of T cell agingStem-cell, NK-cell and exosome technologies are progressing from mechanism to manufacturable products, with manufacturing and regulatory capability now the limiting step.
Manufacturing and supply capability determines which discoveries reach patients.
Source: ISSCRGuidelines for Stem Cell Research and Clinical TranslationNutrition, body composition, muscle mass and mitochondrial function influence nearly every downstream ageing pathway, and are measurable and modifiable at population scale.
Population impact is achievable now, without waiting for novel therapeutics.
Source: World Health OrganizationUN Decade of Healthy Ageing (2021 to 2030)Multi-omic and multimodal models can predict health trajectories, but generalisability across cohorts and ethnicities is the open question. Reporting guidelines are emerging.
Model claims need external validation cohorts before entering clinical or consumer use.
Source: The BMJ, 2024TRIPOD+AI statement: reporting guidance for clinical prediction modelsJoin MR Longevity to find projects, collaborators and capital aligned with this focus.